Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) announced its financial results for the first half of 2026, revealing a notable increase in revenue and significant progress in its U.S. clinical manufacturing program. The company, which combines therapeutic development with a contract development and manufacturing organization (CDMO), reported revenue of $949,000 for the period, up from $773,000 in the prior-year period. This growth reflects the strengthening of its CDMO operations, which have become a key revenue driver.
As of Aug. 16, 2026, Scinai had committed customer orders of approximately $3.1 million, including about $2.1 million already invoiced. The company is actively advancing an expanded clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S.-based biopharmaceutical company. Although a definitive agreement is still under negotiation, Scinai has already received approximately $650,000 in cash payments and advances, with substantive activities underway. This program is designed to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development, positioning Scinai as a critical partner in the late-stage development of a potential new therapy.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half of 2026, compared with $3.8 million in the same period last year. However, the company achieved a net income of approximately $1.6 million, a significant turnaround from a net loss of approximately $4.1 million in the prior-year period. This improvement was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. Cash, cash equivalents, and restricted cash totaled approximately $2.9 million as of June 30, 2026, providing a foundation for ongoing operations and strategic initiatives.
Beyond its CDMO activities, Scinai continues to advance its therapeutic pipeline, including the PC111 and NanoAbs programs. These initiatives reflect the company's commitment to developing innovative immunology therapies. Scinai's pipeline includes candidates licensed from the Max Planck Society and PinCell S.r.l., underscoring its focus on groundbreaking science. The company will host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones, offering stakeholders a comprehensive view of its trajectory.
The expansion of Scinai's U.S. clinical manufacturing program is a strategic move that could significantly enhance its revenue potential. By securing contracts with biopharmaceutical companies, Scinai leverages its state-of-the-art facilities in Jerusalem and Yavne, Israel, to provide essential development and manufacturing services. This dual approach—combining its own therapeutic development with a revenue-generating CDMO—positions Scinai to capitalize on the growing demand for specialized manufacturing capabilities in the biotech industry.
The company's pursuit of approximately $5 million in CDMO revenue for 2026 reflects its confidence in the expanding pipeline of customer projects. As the definitive agreement for the U.S. program progresses, Scinai is poised to solidify its role as a key partner in bringing new therapies to market. The company's ability to generate revenue while advancing its own pipeline offers a balanced model that may appeal to investors seeking both growth and stability.
For more information, visit https://nnw.fm/Be7Ky.
